{"id":"W2591044260","doi":"10.1200/jco.2013.31.15_suppl.4032","title":"Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Temsirolimus; Internal medicine; Everolimus; Bevacizumab; Sunitinib; Clinical endpoint; Phases of clinical research; Progression-free survival; Oncology; Interim analysis; Progressive disease; Response Evaluation Criteria in Solid Tumors; Leukopenia; Gastroenterology; Chemotherapy; Clinical trial; Cancer; PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002560967,0.001207116,0.001015241,0.0003212288,0.0003505163,0.0008303326,0.0005710141,0.001262321,0.004348749],"category_scores_gemma":[0.0009510932,0.0005714336,0.0007182122,0.0002901636,0.0005648297,0.0006770226,0.0003932021,0.002447665,0.0009643518],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000777256,"about_ca_system_score_gemma":0.001405761,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007755898,"about_ca_topic_score_gemma":0.001834314,"domain_scores_codex":[0.9993597,0.000418134,0.00002909262,0.00007994716,0.00003743187,0.00007574826],"domain_scores_gemma":[0.9993405,0.0001020879,0.000116832,0.00003227056,0.00003040981,0.0003779219],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8600243,0.03012983,0.006623299,0.0006099784,0.00100231,0.0002918599,0.0001785706,0.001415425,0.02057397,0.0003952061,0.005799798,0.07295544],"study_design_scores_gemma":[0.7928453,0.1929142,0.007417631,0.00004188844,0.0002405544,0.0002519488,0.00003062789,0.0008923247,0.001469099,0.0001528144,0.003731131,0.00001249926],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9819341,0.005518324,0.0008094027,0.001272065,0.0003069277,0.004605015,0.001521241,0.0001125023,0.003920477],"genre_scores_gemma":[0.9809995,0.002046446,0.002396565,0.001601187,0.0002471612,0.003881095,0.003718854,0.00002747273,0.005081797],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004348749,"threshold_uncertainty_score":0.01454806,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0922024343955625,"score_gpt":0.4789803547000079,"score_spread":0.3867779203044455,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}